Selective 5-HT7 Receptor Modulators via Local Quality
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for CNS and non-CNS disorders related to serotonin receptor dysregulation lack selective modulators that specifically target the 5-HT7 receptor, leading to inadequate therapeutic outcomes.
Innovation Solution
Development of novel compounds with specific structures, such as those described in Formulas (I), (I*), and (I**), which act as selective modulators of the 5-HT7 receptor, allowing for targeted therapy by selectively binding to the 5-HT7 receptor in certain tissues or organs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If non-selective serotonin receptor modulators are used, then broader therapeutic coverage is achieved, but therapeutic specificity and efficacy for 5-HT7 receptor-mediated disorders is reduced
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (Formula I) that possess distinct pharmacological properties tailored for 5-HT7 receptor interaction. The compounds incorporate specific substituents (R1-R9, R4a-R4b, R5 groups) that create localized chemical characteristics enabling selective binding to 5-HT7 receptors over other serotonin receptor subtypes, thereby achieving high receptor selectivity while maintaining therapeutic efficacy for 5-HT7-mediated disorders
2Productivity
If existing serotonin receptor treatments are used, then general serotonin pathway effects are achieved, but selective targeting of 5-HT7 receptors in specific tissues is insufficient
Solution Approach 1:
The patent employs parameter changes by systematically varying molecular parameters (substituent types, positions, and configurations) to optimize the partitioning profile of the compounds across different tissue expressions of 5-HT7 receptors. The compounds incorporate variable groups (R1-R9, R4a-R4b, R5) that can be adjusted to modulate affinity and selectivity for 5-HT7 receptors in specific tissues such as gut, brain, and other organs, thereby achieving superior therapeutic outcomes with controlled receptor targeting
Data Source
AI summary
Described herein are new, selective modulators of the 5-HT7receptor. These selective compounds can be useful for the treatment of CNS and non-CNS indications. Compounds described herein can be selective in targeting 5-HT7 receptors as compared to other receptors and/or by selective targeting 5-HT7 receptors expressed in certain tissues or organs, thereby effective selectivity through a particular partitioning profile of the 5-HT7 modulator